.jpg)
In 2023, we featured Goodair Nosebuds and their path to commercialisation. In September 2025, their first shipment of a thousand units sold out in two days. Inventor Dr David White from the New Zealand College of Chiropractic’s Research Centre says, modestly, of the launch: “It was a good sign”.
Now, in November 2025, they’re filling back orders for this groundbreaking device designed to enhance the body’s natural ability to fight symptoms of nasal congestion and find lasting relief, that's as easy as breathing.
“Through gentle nasal breathing and the modulation of airflow, Nosebuds create a soothing hum, stimulating nasal passages to clear mucus, reduce congestion, and enhance nasal airflow,” says White.
The nasal congestion market is worth tens of billions of dollars if you’re talking about the US, but even in New Zealand White says it’s estimated at $500 million. A 2024 Pharmac report estimates approximately 30 per cent of New Zealanders have some degree of allergic rhinitis. White believes there’s no other device like this on the market.
He credits CEO Dr Kerri McMaster with a crucial decision, saying she not only saw the potential for Goodair Nosebuds,but also found a way for them to get the product to market in just two years.
“One of the biggest challenges with any startup company is getting that critical US FDA approval, and that process can be both time-consuming and costly. Kerri suggested we enter the market as a ‘wellbeing’ device, rather than a class 2 ‘medical device’, as the FDA sets a much lower bar for wellbeing than it does for medical. This meant we could move much more quickly down the commercialisation path,” says White.
“From that soft launch earlier this year, we received lots of feedback and questions from all age groups which will help us move to the next stage of production and distribution.”
White has what he calls ‘one pearl of wisdom’ to offer other innovators aiming for market success. “I always thought Goodair Nosebuds were a medical device until Kerri McMaster suggested the ‘wellbeing’ platform. I strongly recommend innovators critically review the quickest way to market so that they gain oxygen and fuel which offer choices. Without that critical ‘oxygen’ of product revenue, they risk getting stuck because the odds are against medtech with its higher regulatory hurdles. There is a time limit, and innovators must get to their next growth-funding destination.”
Goodair is anticipating a busy year ahead. “We’re focusing on building up stock to enable more retailers to sell Goodair Nosebuds, potential for variations on the product, and a launch into another major country market. We have our eye on that critical FDA approval fora market entry as a medical device, and we have four clinical studies underway,” says White.
Attracting more investor funding is also a priority. “Once our original investors can see that the product is viable and the market accessible, they’re happy to reinvest to support us getting to the next stage.”
Read more about Goodair Nosebuds on their website here: https://goodairnosebuds.com/
